SuperworthLexeo Therapeutics price to book ratio LXEO
Market value divided by the book value of the company's net assets, since 2024.
- Today, Oct 23, 2026
- 1.0×
- 3-year median
- 1.8×
- Against its 3-year history
- 7th
- percentile: 0 is its lowest day, 100 its highest
- 3-year range
- 0.6× to 6.4×
- Peer median
- 4.1×
Lexeo Therapeutics' price to book ratio is 1.0× as of Oct 23, 2026.
That is below its 3-year median of 1.8×, lower than on 93% of days in the last 3 years.
Over that time it ranged from 0.6× in Apr 2025 to 6.4× in Jan 2026.
The median for 3 biotech stocks of a similar size is 4.1×.
Price to book ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 1.0× | 0.9× | 6.4× |
| 2025 | 6.2× | 0.6× | 6.3× |
| 2024 | 1.6× | 1.5× | 3.7× |
Against its peers
Companies in Biotechnology nearest Lexeo Therapeutics' size, closest first, today.
| Company | Price to book ratio |
|---|---|
| LXEOLexeo Therapeutics | 1.0× |
| PLXProtalix BioTherapeutics | 2.9× |
| MGTXMeiraGTx | 4.1× |
| VCELVericel | 5.9× |
| Peer median | 4.1× |
What the price to book ratio tells you
Market value divided by the accounting value of the company's net assets. Below 1 means the market values the business at less than what it owns on paper.
Book value misses brands, software and people, so asset-light companies always look expensive on it. Most useful for banks and industrials.
More on Lexeo Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.